Essa Pharma Acquired by XenoTherapeutics to Advance Prostate Cancer Treatment Innovations
- Essa Pharma completes acquisition by XenoTherapeutics, enhancing focus on innovative prostate cancer therapies.
- Shareholders receive contingent value rights, potentially adding up to $6.7 million based on certain conditions.
- Essa plans to delist from Nasdaq and streamline operations under XenoTherapeutics to advance its drug pipeline.
Essa Pharma Completes Acquisition by XenoTherapeutics, Paving New Path in Prostate Cancer Treatment
Essa Pharma Inc., a pharmaceutical company focused on developing innovative therapies for prostate cancer, finalizes its acquisition by XenoTherapeutics, Inc. The deal, executed through Xeno Acquisition Corp., a wholly-owned subsidiary of Xeno, involves the purchase of all outstanding common shares of Essa at approximately US$0.1242 per share. This acquisition marks a significant step for both companies, as they aim to leverage their respective strengths in research and clinical development. Shareholders of Essa are also set to receive one contingent value right (CVR) per share, offering potential additional payments of up to US$0.14 per CVR, aggregating to a maximum of about US$6.7 million, contingent upon certain liabilities being met.
The Supreme Court of British Columbia grants final approval for the acquisition on October 7, 2025. Following this approval, Essa requests to delist its shares from the Nasdaq Capital Market and plans to terminate its registration under the U.S. Securities Exchange Act of 1934 approximately ten days after the acquisition closure. This strategic decision aligns with Essa's goal of streamlining operations and focusing on the promising prospects of its drug pipeline under the umbrella of XenoTherapeutics. The early warning report regarding the acquisition will be filed on SEDAR+ under Essa's profile, ensuring that shareholders remain informed about the transition.
By joining forces with XenoTherapeutics, Essa Pharma seeks to enhance its research capabilities and broaden its reach in the oncology market, particularly in prostate cancer therapies. XenoTherapeutics, based in Massachusetts, is renowned for its commitment to advancing xenotransplantation through scientific research and public education. With Essa’s established expertise in prostate cancer and Xeno's innovative approach, the acquisition holds the potential to create significant advancements in treatment options for patients battling this prevalent disease.
In addition to the acquisition details, it is noteworthy that Essa Pharma has engaged Leerink Partners LLC as its exclusive financial advisor for this transaction. The legal complexities of the acquisition are managed by Blake, Cassels & Graydon, LLP in Canada and Skadden, Arps, Slate, Meagher & Flom LLP in the U.S., highlighting the meticulous planning and execution behind this strategic move. As Essa transitions into this new phase under XenoTherapeutics, stakeholders remain optimistic about the future of prostate cancer treatments and the potential benefits this merger could bring to patients and the broader medical community.